NASDAQ · Biotechnology

NAGE (NAGE) Stock

$3.12 +2.63% NASDAQ: NAGE Healthcare

Valuation

MetricValue
Price$3.12
Market Cap$248.49M
P/E Ratio18.75
P/B Ratio3.88
P/S Ratio2.31
EPS (TTM)$0.20
52-Week High$14.69
52-Week Low$3.12
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE22.08%
ROA16.04%
ROCE18.42%
Gross Margin10.85%
Operating Margin10.85%
Net Margin14.29%
Debt/Equity0.03
Current Ratio4.85

Annual Financials (USD)

Metric20212022202320242025
Revenue$67.0M$72.0M$84.0M$100.0M$129.0M
Operating Profit$-27.0M$-19.0M$-6.0M$8.0M$14.0M
Net Profit$-27.0M$-17.0M$-5.0M$9.0M$17.0M
EPS$-0.40$-0.24$-0.07$0.11$0.20
Op Margin-40.1%-25.9%-6.7%7.8%11.1%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$58.0M$54.0M$55.0M$68.0M$106.0M
Total Liabilities$26.0M$25.0M$27.0M$22.0M$30.0M
Cash$28.0M$20.0M$27.0M$45.0M$65.0M
Borrowings$5.0M$4.0M$3.0M$3.0M$3.0M

Latest News

Sector Update: Healthcare Stocks Higher Monday Afternoon MT Newswires · Jul 13, 2026 Sector Update: Healthcare MT Newswires · Jul 13, 2026 Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T) Business Wire · Jul 13, 2026 Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026 Business Wire · Jul 9, 2026 Niagen Bioscience Launches Program to Develop Therapies for Accelerated Aging and Rare Genetic Diseases MT Newswires · Jul 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-24.0M$-15.0M$7.0M$12.0M$13.0M
Investing Cash Flow$-1.0M$-1.0M$0$0$-1.0M
Financing Cash Flow$9.0M$0$0$0$0
Net Cash Flow$12.0M$-8.0M$7.0M$17.0M$20.0M
Free Cash Flow$-25.0M$-15.0M$7.0M$12.0M$13.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA15.78
FCF Yield1.34%
Quick Ratio3.55
Interest Coverage—
Return 1Y-67.65%
Return 3Y94.51%
Return 5Y-63.89%

Ownership

Insiders Held29.26%
Institutions Held47.33%
Institutions Float Held66.91%
Institutional HolderSharesReport Date
Blackrock Inc.3,871,6192026-03-31
SteelPeak Wealth, LLC3,500,1292026-06-30
Arrowstreet Capital, Limited Partnership2,378,4372026-03-31
Vanguard Capital Management LLC2,149,2772026-03-31
Tieton Capital Management, LLC2,029,1552026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AKBA $1.31 -0.76% -45.00 $351.42M 0.00%
CRVS $13.31 +3.02% -23.00 $1.12B 0.00%
KALV $27.00 +0.00% -8.28 $1.44B 0.00%
KROS $10.42 +2.06% 4.60 $333.42M 0.00%
OLMA $11.28 -1.48% -3.96 $985.28M 0.00%

About NAGE

NAGE is led by CEO Robert N. Fried, publicly traded since 2015.

NAGE stock trades at $3.12 with a market capitalization of $248.49M. The stock is valued at a price-to-earnings (P/E) ratio of 18.75, price-to-book of 3.88, price-to-sales of 2.31. Over the past 52 weeks the stock has ranged between $3.12 and $14.69, and currently trades 78.8% below its 52-week high.

On profitability, NAGE generates a return on equity (ROE) of 22.08% — well above the market average, a sign of a high-quality business, return on capital employed of 18.42%, an operating margin of 10.85%, a net profit margin of 14.29%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides